Cargando…

Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty

Bone geometry can be described in terms of periosteal and endocortical growth and is partly determined by sex steroids. Periosteal and endocortical apposition are thought to be regulated by testosterone and estrogen, respectively. Gender‐affirming hormone (GAH) treatment with sex steroids in transge...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Loos, Maria ATC, Hellinga, Ilse, Vlot, Mariska C, Klink, Daniel T, den Heijer, Martin, Wiepjes, Chantal M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247856/
https://www.ncbi.nlm.nih.gov/pubmed/33507568
http://dx.doi.org/10.1002/jbmr.4262
_version_ 1783716598070116352
author van der Loos, Maria ATC
Hellinga, Ilse
Vlot, Mariska C
Klink, Daniel T
den Heijer, Martin
Wiepjes, Chantal M
author_facet van der Loos, Maria ATC
Hellinga, Ilse
Vlot, Mariska C
Klink, Daniel T
den Heijer, Martin
Wiepjes, Chantal M
author_sort van der Loos, Maria ATC
collection PubMed
description Bone geometry can be described in terms of periosteal and endocortical growth and is partly determined by sex steroids. Periosteal and endocortical apposition are thought to be regulated by testosterone and estrogen, respectively. Gender‐affirming hormone (GAH) treatment with sex steroids in transgender people might affect bone geometry. However, in adult transgender people, no change in bone geometry during GAH was observed. In this study, we investigated changes in bone geometry among transgender adolescents using a gonadotropin‐releasing hormone agonist (GnRHa) and GAH before achieving peak bone mass. Transgender adolescents treated with GnRHa and subsequent GAH before the age of 18 years were eligible for inclusion. Participants were grouped based on their Tanner stage at the start of GnRHa treatment and divided into early, mid, and late puberty groups. Hip structure analysis software calculating subperiosteal width (SPW) and endocortical diameter (ED) was applied to dual‐energy X‐ray absorptiometry scans performed at the start of GnRHa and GAH treatments, and after ≥2 years of GAH treatment. Mixed‐model analyses were performed to study differences over time. Data were visually compared with reference values of the general population. A total of 322 participants were included, of whom 106 were trans women and 216 trans men. In both trans women and trans men, participants resembled the reference curve for SPW and ED of the experienced gender but only when GnRHa was started during early puberty. Those who started during mid and late puberty remained within the reference curve of the gender assigned at birth. A possible explanation might be sought in the phenomenon of programming, which conceptualizes that stimuli during critical windows of development can have major consequences throughout one's life span. Therefore, this study adds insights into sex‐specific bone geometry development during puberty of transgender adolescents treated with GnRHa, as well as the general population. © 2021 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-8247856
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-82478562021-07-02 Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty van der Loos, Maria ATC Hellinga, Ilse Vlot, Mariska C Klink, Daniel T den Heijer, Martin Wiepjes, Chantal M J Bone Miner Res Original Articles Bone geometry can be described in terms of periosteal and endocortical growth and is partly determined by sex steroids. Periosteal and endocortical apposition are thought to be regulated by testosterone and estrogen, respectively. Gender‐affirming hormone (GAH) treatment with sex steroids in transgender people might affect bone geometry. However, in adult transgender people, no change in bone geometry during GAH was observed. In this study, we investigated changes in bone geometry among transgender adolescents using a gonadotropin‐releasing hormone agonist (GnRHa) and GAH before achieving peak bone mass. Transgender adolescents treated with GnRHa and subsequent GAH before the age of 18 years were eligible for inclusion. Participants were grouped based on their Tanner stage at the start of GnRHa treatment and divided into early, mid, and late puberty groups. Hip structure analysis software calculating subperiosteal width (SPW) and endocortical diameter (ED) was applied to dual‐energy X‐ray absorptiometry scans performed at the start of GnRHa and GAH treatments, and after ≥2 years of GAH treatment. Mixed‐model analyses were performed to study differences over time. Data were visually compared with reference values of the general population. A total of 322 participants were included, of whom 106 were trans women and 216 trans men. In both trans women and trans men, participants resembled the reference curve for SPW and ED of the experienced gender but only when GnRHa was started during early puberty. Those who started during mid and late puberty remained within the reference curve of the gender assigned at birth. A possible explanation might be sought in the phenomenon of programming, which conceptualizes that stimuli during critical windows of development can have major consequences throughout one's life span. Therefore, this study adds insights into sex‐specific bone geometry development during puberty of transgender adolescents treated with GnRHa, as well as the general population. © 2021 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2021-02-17 2021-05 /pmc/articles/PMC8247856/ /pubmed/33507568 http://dx.doi.org/10.1002/jbmr.4262 Text en © 2021 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
van der Loos, Maria ATC
Hellinga, Ilse
Vlot, Mariska C
Klink, Daniel T
den Heijer, Martin
Wiepjes, Chantal M
Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
title Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
title_full Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
title_fullStr Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
title_full_unstemmed Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
title_short Development of Hip Bone Geometry During Gender‐Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty
title_sort development of hip bone geometry during gender‐affirming hormone therapy in transgender adolescents resembles that of the experienced gender when pubertal suspension is started in early puberty
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247856/
https://www.ncbi.nlm.nih.gov/pubmed/33507568
http://dx.doi.org/10.1002/jbmr.4262
work_keys_str_mv AT vanderloosmariaatc developmentofhipbonegeometryduringgenderaffirminghormonetherapyintransgenderadolescentsresemblesthatoftheexperiencedgenderwhenpubertalsuspensionisstartedinearlypuberty
AT hellingailse developmentofhipbonegeometryduringgenderaffirminghormonetherapyintransgenderadolescentsresemblesthatoftheexperiencedgenderwhenpubertalsuspensionisstartedinearlypuberty
AT vlotmariskac developmentofhipbonegeometryduringgenderaffirminghormonetherapyintransgenderadolescentsresemblesthatoftheexperiencedgenderwhenpubertalsuspensionisstartedinearlypuberty
AT klinkdanielt developmentofhipbonegeometryduringgenderaffirminghormonetherapyintransgenderadolescentsresemblesthatoftheexperiencedgenderwhenpubertalsuspensionisstartedinearlypuberty
AT denheijermartin developmentofhipbonegeometryduringgenderaffirminghormonetherapyintransgenderadolescentsresemblesthatoftheexperiencedgenderwhenpubertalsuspensionisstartedinearlypuberty
AT wiepjeschantalm developmentofhipbonegeometryduringgenderaffirminghormonetherapyintransgenderadolescentsresemblesthatoftheexperiencedgenderwhenpubertalsuspensionisstartedinearlypuberty